{"abstract":"The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Ankarys Therapeutics Inc., located at 110 Cumberland Street, Suite 520, M5R 3V5, Toronto, Ontario, Canada, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.","action":"Notice.","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"},{"raw_name":"National Institutes of Health","name":"National Institutes of Health","id":353,"url":"https://www.federalregister.gov/agencies/national-institutes-of-health","json_url":"https://www.federalregister.gov/api/v1/agencies/353","parent_id":221,"slug":"national-institutes-of-health"}],"body_html_url":"https://www.federalregister.gov/documents/full_text/html/2021/10/22/2021-23092.html","cfr_references":[],"citation":"86 FR 58681","comment_url":null,"comments_close_on":"2021-11-08","correction_of":null,"corrections":[],"dates":"Only written comments and/or applications for a license which are received by the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases on or before November 8, 2021 will be considered.","disposition_notes":null,"docket_ids":[],"dockets":[],"document_number":"2021-23092","effective_on":null,"end_page":58682,"executive_order_notes":null,"executive_order_number":null,"full_text_xml_url":"https://www.federalregister.gov/documents/full_text/xml/2021/10/22/2021-23092.xml","html_url":"https://www.federalregister.gov/documents/2021/10/22/2021-23092/prospective-grant-of-exclusive-patent-commercialization-license-cd28h-domain-containing-chimeric","images":{},"images_metadata":{},"json_url":"https://www.federalregister.gov/api/v1/documents/2021-23092?publication_date=2021-10-22","mods_url":"https://www.govinfo.gov/metadata/granule/FR-2021-10-22/2021-23092/mods.xml","not_received_for_publication":null,"page_length":2,"page_views":{"count":219,"last_updated":"2026-07-28 14:15:04 -0400"},"pdf_url":"https://www.govinfo.gov/content/pkg/FR-2021-10-22/pdf/2021-23092.pdf","presidential_document_number":null,"proclamation_number":null,"public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2021-23092.pdf?1634820334","publication_date":"2021-10-22","raw_text_url":"https://www.federalregister.gov/documents/full_text/text/2021/10/22/2021-23092.txt","regulation_id_number_info":{},"regulation_id_numbers":[],"regulations_dot_gov_info":{"checked_regulationsdotgov_at":"2023-02-28T17:41:36Z"},"regulations_dot_gov_url":null,"significant":null,"signing_date":null,"start_page":58681,"subtype":null,"title":"Prospective Grant of Exclusive Patent Commercialization License: CD28H Domain-Containing Chimeric Antigen Receptors and Methods of Use","toc_doc":"CD28H Domain-Containing Chimeric Antigen Receptors and Methods of Use","toc_subject":"Prospective Grant of Exclusive Patent Commercialization License:\n","topics":[],"type":"Notice","volume":86}